Emergent Biosolutions

Emergent BioSolutions is a life sciences company. The company has four business units: Vaccines and Anti-Infectives, which contains a portfolio of specialty vaccines and anti-infectives that address existing and emerging public health threats (PHTs); Devices, which contains a portfolio of drug-device combination products; Antibody Therapeutics, which contains a portfolio of specialty antibody-based therapeutics and prophylactics that address a range of existing and emerging PHTs; and Contract Development and Manufacturing, which consists of a range of contract development and manufacturing services, directed to both internal products owned by the company as well as to third-party customers with needs.
  • TickerEBS
  • ISINUS29089Q1058
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Moody's assigns Ba2 CFR to Emergent BioSolutions

Rating Action: Moody's assigns Ba2 CFR to Emergent BioSolutions. Global Credit Research- 04 Aug 2020. New York, August 04, 2020-- Moody's Investors Service assigned first-time ratings to Emergent BioSolutions Inc. including a Ba2 Corporate Family Rating, a Ba2-PD Probability of Default Rating, a Ba3 senior unsecured rating, and an SGL-1 Speculative Grade Liquidity Rating.

Emergent BioSolutions Inc.: Key factors leading to first-time Ba2 Corporate Family Rating

The credit profile reflects a niche focus on public health threats, capabilities in vaccine manufacturing, and moderate financial leverage, tempered by US government customer concentration

Moody's assigns Ba2 CFR to Emergent BioSolutions

Rating Action: Moody's assigns Ba2 CFR to Emergent BioSolutions. Global Credit Research- 04 Aug 2020. New York, August 04, 2020-- Moody's Investors Service assigned first-time ratings to Emergent BioSolutions Inc. including a Ba2 Corporate Family Rating, a Ba2-PD Probability of Default Rating, a Ba3 senior unsecured rating, and an SGL-1 Speculative Grade Liquidity Rating.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-term ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold and...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of names in the Communications Sector are showing signs of leadership. (ex. GLUU, and CNSL) • Consumer Discretionary continues to have a number of attractive names technically. (ex. TXRH, BLMN, WEN, CBRL, SCI, LL, and STMP) • Healthcare has a number of attractive names technically. (ex. SEM, CYH, THC, PRSC, TRHC, HQY, GILD, EBS, REGN, and ABBV) • REIT's remain a leadership Sector (ex. STAR, HR, SAFE, DLR, SBAC, and EQIX)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. · Short-Term Levels. The S&P 500 is at the upper-end of ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Key Resistance As we have outlined in recent weeks, our base case continues to be for near-term consolidation while the market is in a “wait-and-see” phase as it relates to states re-opening. The S&P 500 is again testing key resistance at the 61.8% Fibonacci retracement level of 2934.49 and also the 2950-3000 level we previously identified. We continue to have concerns that lead us to believe the market is not yet out of the woods, however these concerns are counterbalanced by a number of positive developments. When it comes down to it, key support levels mentioned last week i...

Moody's assigns Ba2 CFR to Emergent BioSolutions

Rating Action: Moody's assigns Ba2 CFR to Emergent BioSolutions. Global Credit Research- 04 Aug 2020. New York, August 04, 2020-- Moody's Investors Service assigned first-time ratings to Emergent BioSolutions Inc. including a Ba2 Corporate Family Rating, a Ba2-PD Probability of Default Rating, a Ba3 senior unsecured rating, and an SGL-1 Speculative Grade Liquidity Rating.

Emergent BioSolutions Inc.: Key factors leading to first-time Ba2 Corporate Family Rating

The credit profile reflects a niche focus on public health threats, capabilities in vaccine manufacturing, and moderate financial leverage, tempered by US government customer concentration

Moody's assigns Ba2 CFR to Emergent BioSolutions

Rating Action: Moody's assigns Ba2 CFR to Emergent BioSolutions. Global Credit Research- 04 Aug 2020. New York, August 04, 2020-- Moody's Investors Service assigned first-time ratings to Emergent BioSolutions Inc. including a Ba2 Corporate Family Rating, a Ba2-PD Probability of Default Rating, a Ba3 senior unsecured rating, and an SGL-1 Speculative Grade Liquidity Rating.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch